TY - JOUR
T1 - AllergoOncology
T2 - Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI-EANO position paper
AU - Turner, Michelle C.
AU - Radzikowska, Urszula
AU - Ferastraoaru, Denisa E.
AU - Pascal, Mariona
AU - Wesseling, Pieter
AU - McCraw, Alexandra
AU - Backes, Claudine
AU - Bax, Heather J.
AU - Bergmann, Christoph
AU - Bianchini, Rodolfo
AU - Cari, Luigi
AU - de las Vecillas, Leticia
AU - Izquierdo, Elena
AU - Lind-Holm Mogensen, Frida
AU - Michelucci, Alessandro
AU - Nazarov, Petr V.
AU - Niclou, Simone P.
AU - Nocentini, Giuseppe
AU - Ollert, Markus
AU - Preusser, Matthias
AU - Rohr-Udilova, Nataliya
AU - Scafidi, Andrea
AU - Toth, Reka
AU - van Hemelrijck, Mieke
AU - Weller, Michael
AU - Jappe, Uta
AU - Escribese, Maria M.
AU - Jensen-Jarolim, Erika
AU - Karagiannis, Sophia N.
AU - Poli, Aurélie
N1 - Publisher Copyright: © 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2024/6
Y1 - 2024/6
N2 - Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.
AB - Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.
KW - IgE
KW - atopy
KW - brain cancer
KW - epidemiology
KW - neuroimmunology
UR - http://www.scopus.com/inward/record.url?scp=85183058054&partnerID=8YFLogxK
U2 - 10.1111/all.15994
DO - 10.1111/all.15994
M3 - Article
C2 - 38263898
SN - 0105-4538
VL - 79
SP - 1419
EP - 1439
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 6
ER -